Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market
While Esperion’s investors have been through a roller coaster of reactions on whether or not the FDA was willing to accept LDL lowering as a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
